SARS-CoV-2 vaccination and new-onset myasthenia gravis: A report of 7 cases and review of the literature

Neuromuscul Disord. 2022 Oct;32(10):785-789. doi: 10.1016/j.nmd.2022.09.001. Epub 2022 Sep 5.

Abstract

Myasthenia gravis (MG) is an antibody-mediated immune disorder of the neuromuscular junction. SARS-CoV-2 is now recognised as a trigger factor for autoimmune diseases and to cause immune-mediated dysregulation, likely due to molecular mimicry induced by viral antigens. SARS-CoV-2 vaccination, similarly, results in exposure to viral antigen. Here we report 7 cases of new-onset myasthenia gravis in timely association with SARS-CoV-2 vaccination, including the first paediatric case identified to date. We also reviewed the literature for other new-onset MG cases reported within 4 weeks of SARS-CoV-2 vaccination and discuss our findings in the context of altered (auto)immunity following SARS-CoV-2 vaccination and/or infection.

Keywords: Myasthenia gravis; SARS-CoV-2; Vaccination.

Publication types

  • Review
  • Case Reports

MeSH terms

  • COVID-19 Vaccines / adverse effects
  • COVID-19* / prevention & control
  • Child
  • Humans
  • Myasthenia Gravis* / complications
  • SARS-CoV-2
  • Vaccination / adverse effects

Substances

  • COVID-19 Vaccines